Biblio
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. Eur J Haematol. 2020.
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. Vnitr Lek. 2016;62(1):25-39.
.